EDITOR’S NOTE: With this new application, LyGenesis will move forward with a Phase 2a study on the safety, tolerance and efficacy of its novel cell therapy for end stage liver disease.
EDITOR’S NOTE: With this new application, LyGenesis will move forward with a Phase 2a study on the safety, tolerance and efficacy of its novel cell therapy for end stage liver disease.
3D bioprinting is a mind-boggling technology that emerged in the 21st century. The idea of lab-grown tissues could mean the end of testing drugs on animals and humans, and it could be the solution for organ shortages, ending the desperate state of organ donations worldwide.